PATENT CLAIM ANALYSIS

Application Number: 15927675
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["424", "133100"]

Abstract:
This disclosure provides anti-CXCR5 antibodies and their use in the amelioration, treatment, or prevention of lupus. The disclosure also provides prophylactic, immunotherapeutic, and diagnostic compositions comprising an anti-CXCR5 antibody, and the use of such anti-CXCR5 antibodies in methods of preventing or treating lupus in mammals, including humans.

Claim (Index 3):
A method of treating a patient having lupus, comprising administering to the patient a therapeutically effective amount of an antibody or fragment thereof that specifically binds to the extracellular domain of human CXCR5, wherein the antibody or fragment thereof comprises the amino acid sequences of RSSKSLLHSSGKTYLY (SEQ ID NO: 58), RLSSLA (SEQ ID NO: 68), MQHLEYPYT (SEQ ID NO: 60), GFSLIDYGVN (SEQ ID NO: 61), VIWGDGTTY (SEQ ID NO: 62), and IVY (SEQ ID NO: 63); and\n wherein the patient has tested positive for antinuclear antibody with a titer of \u22651:160.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 90.0
- Lexical Diversity: 1.61765
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13794264', '12675799', '13794224', '13794244', '13794281']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7294824260271218
- 35 USC 102 Novelty (BERT): 0.5409069705748761
- Combined Prediction Score: 0.7106248804818972
- Mean Citation Score: 372.564536
- Max Citation Score: 388.645
- Similarity Product: 377.4369394031166

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test